KRAS, KRAS proto-oncogene, GTPase, 3845

N. diseases: 1213; N. variants: 54
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Importantly, KRAS was proved to mediate LINC01420-facilitated PC cell proliferation. 31562613 2020
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. 31230347 2020
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. 30653981 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 AlteredExpression disease BEFREE The aforementioned results indicate that KIS37 administration is a novel therapeutic strategy for targeting PDK4 in KRAS-activated intractable human pancreatic cancer. 31106493 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Hyperinsulinemia is a risk factor for pancreatic cancer, but the function of insulin in carcinogenesis is unclear, so this study aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer. 30838710 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE We conclude that EGFR-targeted RIT with panitumumab-MCP-<sup>177</sup>Lu was able to overcome resistance to panitumumab in KRAS mutant PANC-1 tumors in NRG mice and may be a promising approach to treatment of PnCa in humans. 30589553 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Addition of analysis of KRAS mutation or immunohistochemistry with MUC1 and carcinoembryonic antigen improves the diagnostic performance of fine needle aspiration cytology for the diagnosis of pancreatic carcinoma. 30929285 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE We identified several cancer-related SAAVs including KRAS, which is an important oncoprotein in pancreatic cancer. 30404448 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Further workup revealed that circulating tumor-derived DNA and liver metastases originated from a synchronous KRAS-mutated cancer of the pancreas. 31134762 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Hence, simultaneously targeting both the TGF-β and KRAS pathways might dismantle the obstacles of pancreatic cancer therapy. 31033217 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE The same missense variants between the initial tumor and remnant PC were discovered only in KRAS of one patient, and in HRAS of one patient. 30515563 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. 31311847 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE The KRAS gene is the most frequently mutated gene in pancreatic cancer, and no successful anti-Ras therapy has been developed. 31268978 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Importantly, T-UPSM demonstrated superior safety and antitumor efficacy over triptolide and T-NPSM in KRAS mutant pancreatic cancer mouse models. 30912923 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. 31406261 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. 31227505 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Initially demonstrated in oncogenic KRAS-driven models of pancreatic cancer, macropinocytosis triggers the internalization of extracellular proteins via discrete endocytic vesicles called macropinosomes. 30967003 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE PC significantly inhibited the viability of KRAS mutant pancreatic cancer cells (PANC-1 and MiaPaCa-2) in a dose-dependent manner; however, it did not affect the wild type KRAS pancreatic cancer cells (BxPC-3). 30716311 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Western blot analysis revealed that LY-1816 markedly suppressed the Src signaling, and downregulated the expression of FOSL1; FOSL1 is an oncogene vulnerability in KRAS-driven pancreatic cancer. 30618127 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Our data suggest a crucial role of LIF in KRAS-driven pancreatic cancer and that blockade of LIF by neutralizing antibodies represents an attractive approach to improving therapeutic outcomes. 31296870 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) has been depicted as a therapeutic target in pancreatic cancer for many years. 28639199 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE Targeting EphA2 with miR-124 mediates Erlotinib resistance in K-RAS mutated pancreatic cancer. 30604411 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 GeneticVariation disease BEFREE KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer. 30876538 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 Biomarker disease BEFREE Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. 31263025 2019
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma
0.700 AlteredExpression disease BEFREE KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. 31375828 2019